公司地址：
535 Bourke Street,Level 22,Melbourne,Victoria,Australia
简介：
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with erythropoietic protoporphyria in the People's Republic of China. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.